Early DiAgnosis Real-Time Healthcare System for CANcer Trial
NCT ID: NCT05064124
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
420 participants
OBSERVATIONAL
2024-07-18
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The CADDIE device is capable of recording the video output of the colon in real-time irrespective of whether the CADDIE's AI system is active.
In the endoscopist recruitment phase, we will identify endoscopists expertise and experience in colonoscopy.
In the study phase of the trial, the endoscopist will be kept the same for the CADDIE and control arm. At the beginning of each procedure, participant information will be entered into an electronic system (Redcap) which will generate a random allocation into one of two arms. The CADDIE arm involves a colonoscopy assisted by the CADDIE AI system (i.e., AI software). The control arm is a colonoscopy without the CADDIE's polyp characterisation AI system (i.e., standard practice). Each endoscopist will have the CADDIE device present during all endoscopy lists and will record all procedures in both CADDIE and control arms. The CADDIE's polyp characterisation system (i.e., AI software) will only be active in the CADDIE arm. The recordings in the control arms will allow an extra post-hoc assessment of how CADDIE might have performed compared to the actual assessment by the endoscopist.
In both arms of the trial, for each polyp the endoscopist detects, they will:
1. Measure the polyp size and capture images of the polyp:
Polyps are to be measured using an instrument of known size. For polyps measured to be \<10mm, the endoscopist will capture a still image of the polyp in both white light and Narrow Band Imaging (NBI) or equivalent imaging modality.
2. Optically diagnose the polyp:
The endoscopist will optically diagnosis polyps \<10mm, stating whether the diagnosis is made with high or low confidence.
3. Resect diminutive polyps:
Management of rectosigmoid hyperplastic polyps will be standardised. Rectosigmoid polyps that are optically diagnosed as hyperplastic by the endoscopist will be resected/biopsied. If multiple rectal hyperplastic polyps are optically diagnosed by the endoscopist, a maximum of 5 will be resected/biopsied for histopathology.
4. Label the polyp with unique ID:
Each polyp resected (regardless of size) must be labelled according to instructions of the Specimen Handling SOP. Each unique polyp ID will be logged in chronological order on a per colonoscopy basis and sent for histopathology. Histopathology will be referenced as the ground truth for polyp diagnosis and characterisation.
5. Complete documentation as per standard of care:
Documentation will be made in the endoscopy report of polyp site, size, morphology, segmental Boston Bowel Preparation Score (BBPS). A photograph will also be taken of the caecum and stored in the endoscopy report.
6. Complete the optical diagnosis case report form (CRF):
Populate the optical diagnosis CRF at the end of the procedure with the polyp ID of each polyp sample (regardless of size), their optical diagnosis of each polyp \<10mm in size and whether their optical diagnosis was made with high or low confidence.
In the CADDIE arm, the endoscopist presses the foot pedal once they have frozen an image of the polyp in the endoscopy screen in narrow band imaging (NBI) mode. This will output the CADDIE's characterisation of the polyp. Using this information and the endoscopist's own assessment, the endoscopist will log an optical diagnosis of the polyp and the confidence of their diagnosis (high or low). In the control arm, the endoscopist optically diagnoses the polyps without CADDIE's polyp characterisation function. The optical diagnosis will be assessed against the polyp histopathology which will be referred as the ground truth. Post-hoc analysis of the recorded footage will allow for comparison with the CADDIE generated polyp characterisation.
Safety of the device will be assessed through monitoring of adverse events. Acceptability will be assessed through a qualitative questionnaire for the endoscopist, endoscopy nurse and participant in addition to measuring endoscopy markers such as caecal intubation time, procedural time, withdrawal time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CADDIE
Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system
CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy
1. CADDIE assisted polyp detection
2. CADDIE assisted polyp characterisation
Control group
Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy
1. CADDIE assisted polyp detection
2. CADDIE assisted polyp characterisation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female participants aged 18 years or older at the time of informed consent.
* Participants able to comprehend, sign and date the written informed consent document to participate in the study.
Exclusion Criteria
* Participants with inflammatory bowel disease (IBD)
* Participants with current Colorectal Cancer (CRC)
* Participants with a contraindication for biopsy or polypectomy. These include:
* Participants who have not withheld medications pre-disposing to bleeding at time of colonoscopy as per local site /national guidelines.
* Participants with a history of haemostasis disorders (haemostasis disorders will include but will not be limited to: participants with haemophilia or other congenitally acquired clotting factor deficiencies, participants with cirrhosis with coagulopathy, participants known to have thrombocytopenia (\<80,000 platelet/ul) and individuals with Von Willebrand's disease or other known platelet malfunction disorders)
* Participant is enrolled in another research study with an investigational medicinal product (IMP) or non-IMP that pre-disposes them to bleeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manish Chand, MBBS FRCS PhD
Role: PRINCIPAL_INVESTIGATOR
UCL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College London Hospitals NHS Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Manish Chand, MBBS FRCS PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
143608
Identifier Type: -
Identifier Source: org_study_id